Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
about
The role of neoadjuvant therapy in the management of locally advanced renal cell carcinomaCytoreductive surgery in the era of targeted molecular therapyNeoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesisSurgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinomaNeoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments.Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy.Molecular diagnosis and therapy of kidney cancer.Targeted therapies for non-clear renal cell carcinoma.Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.The prospects of pazopanib in advanced renal cell carcinoma.The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancerPhase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable?Complete response of sunitinib therapy for renal cell cancer recurrence in the native kidney after renal transplantation: a case reportPhase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures.The current role of lymph node dissection in the management of renal cell carcinoma.Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.Small Cell Cancer of the Bladder and Prostate: A Retrospective Review from a Tertiary Cancer CenterMET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors.Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.Update on targeted therapies for clear cell renal cell carcinomaVascularity of primary and metastatic renal cell carcinoma specimens.Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.Clinical and histopathological effects of presurgical treatment with sunitinib for renal cell carcinoma with inferior vena cava tumor thrombus at a single institution.p75 neurotrophin receptor and pro-BDNF promote cell survival and migration in clear cell renal cell carcinoma.A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma.Adjuvant and neoadjuvant therapy in renal cell carcinoma.Sunitinib for the management of advanced renal cell carcinoma.Is there a role for presurgical therapy for renal cell carcinoma?Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?Long-term management of patients with metastatic renal cell carcinoma on targeted agents.Surgical management of large renal tumors.Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus.Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives.Improved survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the era of targeted therapy.Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.
P2860
Q26749084-95657513-B757-481D-980B-1A20E33CEFA2Q26774134-CCA3C443-0E32-4C4C-9EE2-90E0A1C5BB6AQ27002583-56503AE2-A04B-4375-827C-2CD034ED0BC8Q28087518-6B2FBD20-9CA1-446A-9EA8-F33613900ED8Q29614537-903DFDBC-0963-40CA-8FC0-7205BE0E404FQ33740717-77B72399-5FDA-4DBD-9314-9D7AEFDE4C39Q33754122-658CD44A-9BED-4477-BA1E-1F1A09B960B2Q33891216-1C135DB3-27F7-4F17-AAEC-C1B4743405D0Q34005262-AA50C462-05E1-4FC2-8409-3D47C8AB5388Q34065685-EF032E32-B350-48B8-BDEC-F4A3429BD361Q34412479-F6C4E814-9289-42B5-BFD1-C66DEFC92512Q34572309-62E6C4AE-E708-4553-9BFD-42E158F1D7FBQ34656393-D0CE4B5C-5C55-45DE-8CC0-6054648F39C1Q34854084-A418D653-2ECF-43DD-8C59-DFA60C612DC4Q35210685-BC8E6BCF-6C44-4210-B187-637F1A769610Q35218774-A2D47BA8-0E5C-4FDE-94A6-C84613D9D04CQ35225322-E472B354-FD2C-451C-B052-00D7C2D38AD4Q35413876-58A76F6B-5F8B-4B00-9858-78A478A08C8DQ35684252-B9CA89CE-81F0-4029-A662-899B1C2F81B3Q35687604-314C44FC-62C5-4770-9773-C0C825DD75E0Q35916894-D07B9DA2-4A68-428C-9159-2FFC7AA7ADA2Q35928857-AEA29865-A3C2-406B-B0AE-1D35DB564F62Q36095630-5F064419-891C-4AE6-8647-E8E82A5824A4Q36344279-CCBAEC96-589A-43DB-A312-2753D1F4E3B0Q36369380-E25EE395-D590-426D-BB9B-EBA0F048AF6BQ36578610-3C6CD036-045D-4AAD-9CD3-E1E9FC9D3AE0Q37205794-E912238B-C312-473E-B06C-0BC073B81978Q37309626-F91EEDDD-B4BA-42A0-8254-0EF8EC1A712CQ37376314-42378DFA-9700-4922-9DD9-2B8F7B8842C2Q37404963-22EE3638-412A-42F8-8561-8087F93C2D00Q37492442-82291FB8-8C2E-47C4-9139-A864D9866D4AQ37705402-B62D8D9E-4DFE-492A-A6A7-2EB6FAA5B44FQ37765582-1E65865B-C8DB-4466-BF47-09FB45170672Q37772190-440B83FD-5D1E-4AA1-BF58-5E5F21AA5230Q37812603-92C2DC9F-9926-4285-BBD8-631E0BC31041Q37960913-EF05EB3F-00D8-42C5-956E-E0718632A112Q38005998-C769502F-B6FC-4A2A-A2D2-EFBD856B410AQ38068585-B166CA5B-A49F-450A-B1BF-92F42F75826FQ38132624-EEEB6FE9-E890-4EDD-B5A2-FE3187B85B47Q38171327-6C4343A1-3627-4E52-BBAD-7AE81C00068A
P2860
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Neoadjuvant targeted therapy a ...... for a new treatment paradigm.
@en
Neoadjuvant targeted therapy a ...... for a new treatment paradigm.
@nl
type
label
Neoadjuvant targeted therapy a ...... for a new treatment paradigm.
@en
Neoadjuvant targeted therapy a ...... for a new treatment paradigm.
@nl
prefLabel
Neoadjuvant targeted therapy a ...... for a new treatment paradigm.
@en
Neoadjuvant targeted therapy a ...... for a new treatment paradigm.
@nl
P2093
P1433
P1476
Neoadjuvant targeted therapy a ...... for a new treatment paradigm.
@en
P2093
Allan J Pantuck
Arie S Belldegrun
Brian Shuch
Fairooz F Kabbinavar
Jeff C LaRochelle
Raffi Avakian
Stephen B Riggs
P304
P356
10.1111/J.1464-410X.2008.07660.X
P577
2008-04-10T00:00:00Z